Fig 2: SLC34A2 expression is negatively correlated with the overall survival and event-free survival of neuroblastoma patients. (A–F) KM-Plotter analysis showed the correlation between SLC34A2 expression and overall survival (A–C) and relapse-free survival (D–F) of neuroblastoma patients.

Fig 3: SLC34A2 promotes the stemness of neuroblastoma cells. (A) Representative image of spheroids formed by SH-SY5Y cells. Scale bar, 100 µm. (B,C) SLC34A2 expression was detected in SH-SY5Y cells and spheroids. (D,E) Expression of stemness markers (ALDH1 and Nanog) was examined in SH-SY5Y cells and spheroids. (F,G) Expression of stemness markers was determined in SH-SY5Y cells with or without SLC34A2 overexpression. (H) The capacity of spheroid formation was evaluated in cells depicted in (F). Scale bar, 100 µm. (I,J) Expression of stemness markers was measured in SH-SY5Y cell spheroids with or without SLC34A2 knockdown. (K) The capacity of spheroid formation was detected in spheroids described in (I). (L,M) The overexpression and knockdown efficiency of SLC34A2 was confirmed in SH-SY5Y cells and spheroids, respectively. The difference was assayed using one-way ANOVA with the Tukey–Kramer post hoc test. Data are presented as mean ± SD; n = 3, **P < 0.01 vs control.

Fig 4: SLC34A2 attenuates the stemness of neuroblastoma cells through miR-25–Gsk3ß axis. (A) MiR-25 and Gsk3ß expression was detected in SH-SY5Y cells with SLC34A2 overexpression plus miR-25 knockdown or Gsk3ß overexpression. (B,C) Expressions of stemness markers were measured in cells depicted in (A). (D,E) The capacity of spheroid formation was determined in cells described in (A) by detecting the spheroid size (D) and number (E). Scale bar, 100 µm. (F,G) Expression of Wnt3a and ß-catenin was examined in cells depicted in (A). The difference was assayed using one-way ANOVA with the Tukey–Kramer post hoc test. Data are presented as mean ± SD; n = 3, *P < 0.05, **P < 0.01 vs control.